<DOC>
	<DOCNO>NCT02072616</DOCNO>
	<brief_summary>Histological proof crucial necessary step appropriate care oncology . In case pancreatic cancer , histological proof pathological analysis surgical specimen rare due limited number ( 15-20 % ) localize tumor accessible surgical resection . In case , invasive endoscopic exploration necessary histological diagnosis decide appropriate treatment ( palliative chemotherapy radiochemotherapy ) . The endoscopic ultrasound fine needle aspiration ( EUS-FNA ) currently consider first-line endoscopic procedure cytological diagnosis solid pancreatic tumor . The technique perform general anesthesia sensitivity diagnosis adenocarcinoma 80 % case single procedure 92 % situation three different procedure require . EUS-FNA perform physician properly train type interventional endoscopy . Some severe complication may occur relatively rare expert center ( bleed , perforation , complication general anesthesia ... ) . Diagnostic alternative approach biological research peripheral blood marker tumor disease . It possible detect indirect marker molecule produce tumor tissue ( eg CA19.9 ) direct marker reflect presence tumor biological material ( circulate tumor cell ( CTCs ) circulate tumor DNA ) . The value detection CTCs determine diagnostic therapeutic management pancreatic cancer . Indeed , study evaluate diagnosis performance circulate marker EUS-FNA , reference method diagnosis unresectable form .</brief_summary>
	<brief_title>Detection Circulating Tumor Cells Diagnostic Pancreatic Adenocarcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Patient male female , &gt; 18 year age Patient nonmetastatic solid pancreatic tumor ( proved CT thoracoabdominopelvic ) without histological evidence Patient refer surgical treatment biliopancreatic endoscopic ultrasound fine needle aspiration ( EUSFNA ) pancreatic mass Patient agree participate give write informed consent metastatic pancreatic tumor cancer hematologic malignancy treatment remission le 5 year . minor patient 18 year contraindication surgical treatment contraindication biliopancreatic EUSFNA patient guardianship Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Circulating Tumor Cells</keyword>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>circulate tumor DNA ( KRAS )</keyword>
	<keyword>CA 19.9</keyword>
</DOC>